Back to search results

Phase 2/3 Study of VX-147 for APOL1-Mediated Proteinuric Kidney Disease

This study is testing a drug called VX-147 in adults and children with a specific type of kidney disease called APOL1-mediated proteinuric kidney disease. This condition causes too much protein in your urine. Researchers want to see how well VX-147 works, if it's safe, and how your body handles it. You might be able to join if you are between 10 and 65 years old and have the specific APOL1 gene type and proteinuric kidney disease. The study will look at changes in protein in your urine and how your kidney function (eGFR) changes over time. The current status of this study is unclear, and it plans to enroll 466 participants.

Study design
This is an interventional study where participants will receive either VX-147 tablets or placebo tablets. It is designed to enroll 466 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your kidney function will be assessed from baseline through at least 2 years of study completion.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05312879

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

Recruiting
PHASE2Ages 10–65InterventionalTreatment
Vertex Pharmaceuticals Incorporated
~466 participants
Updated 2026-08-26 on ClinicalTrials.gov
What's tested:VX-147Placebo

At a glance

Recruiting sites
229 of 318 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Part A: Percent Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48 (Assessed at the Week 48 Interim Analysis)
Measured over From Baseline to Week 48
+3 more outcomes measured

Conditions

Proteinuric Kidney Disease

Explore related trials

APOL1-mediated kidney diseaseProteinuric Kidney DiseaseAPOL1 Gene

Where it's being run

318 sites across 46 states
Brazil29
Texas27
Florida24
Georgia22
United Kingdom18
New York17
California12
France12

Who to contact

Medical Information
[email protected]
617-341-6777
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

APOL1 genotype of G1/G1, G2/G2, or G1/G2
Proteinuric kidney disease

Exclusion

Solid organ or bone marrow transplant
Uncontrolled hypertension
History of diabetes mellitus
Known underlying cause of kidney disease including but not limited to sickle cell disease
ESKD (End Stage Kidney Disease) as defined in the protocol.
Any lab abnormality that may pose a safety risk to the participant, as judged by the investigator.

What this trial measures

  • Part A: Percent Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48 (Assessed at the Week 48 Interim Analysis)From Baseline to Week 48
  • Part A: Estimated Glomerular Filtration Rate (eGFR) Slope Assessed at Interim AnalysisFrom Baseline Through >= Week 48
  • Part A: eGFR Slope Assessed at Final AnalysisFrom Baseline Through Study Completion (At least 2 years of eGFR data assessed at the final analysis)
  • Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse events (AEs) and Serious Adverse Events (SAEs)Day 1 Through Study Completion (Approximately 4 Years After the Last Participant Enrolls)